Tarsus Pharmaceuticals Inc
TARS
Company Profile
Business description
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.
Contact
15440 Laguna Canyon Road
Suite 160
IrvineCA92618
USAT: +1 949 418-1801
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
370
Stocks News & Analysis
stocks
Weak investor sentiment for cheap ASX
Earnings growth maintained despite turbulent market conditions.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,016.10 | 57.40 | 0.64% |
| CAC 40 | 8,319.67 | 257.36 | 3.19% |
| DAX 40 | 25,137.87 | 736.17 | 3.02% |
| Dow JONES (US) | 49,298.25 | 356.35 | 0.73% |
| FTSE 100 | 10,463.81 | 244.70 | 2.39% |
| HKSE | 26,213.78 | 315.17 | 1.22% |
| NASDAQ | 25,326.13 | 258.33 | 1.03% |
| Nikkei 225 | 59,513.12 | 228.20 | 0.38% |
| NZX 50 Index | 13,145.19 | 109.49 | 0.84% |
| S&P 500 | 7,259.22 | 58.47 | 0.81% |
| S&P/ASX 200 | 8,793.60 | 58.60 | 0.67% |
| SSE Composite Index | 4,160.17 | 48.01 | 1.17% |